Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Connect Tissue Res ; 54(6): 426-31, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24020358

RESUMO

There is increasing evidence that oxidative stress, due to estrogen deficiency, leads to osteopenia. In this study, dimethyl sulfoxide (DMSO), an antioxidant solvent, was used against post-ovariectomy osteopenia (PO) in rats. Forty female rats were divided into 5 groups randomly as follows: Sham, control group; OVX, ovariectomized group; DMSO1, ovariectomized injected DMSO (0.5 ml/kg/d ip); DMSO2, ovariectomized injected DMSO (1 ml/kg/day ip) and DMSO3, ovariectomized injected DMSO (2 ml/kg/d ip). DMSO therapy started 1 week after ovariectomy and continued for 13 weeks. After 13th weeks, sera were prepared, and then L4 vertebrae and right tibial bones rinsed in fixative. Serum bone alkaline phosphatase (BALP), osteocalcin, pyridinoline, malondialdehyde (MDA) and glutathione (GSH) were measured. Trabecular volume density, trabecular and cortex thickness were estimated. Osteoclast and osteoblast numbers were counted morphometrically. The data were analyzed by ANOVA and then post hoc Tukey test at p < 0.05. The increase of pyridinoline and decrease of BALP in DMSO injected groups were inhibited compared with OVX group (p < 0.05). In DMSO injected groups, decrease of bone density, trabecular volume density, thickness of trabecular and tibial cortex were inhibited compared with OVX group (p < 0.05). MDA decreased significantly in DMSO injected groups compared with OVX group. Osteoclast number decreased in DMSO injected groups compared with OVX group (p < 0.05). Osteoblast number did not show significant change in DMSO groups compared with OVX group. In conclusion, DMSO ameliorates PO through decrease of osteoclast number, osteoclast inhibition and osteoblast activation. These effects may probably be mediated via antioxidant property of DMSO.


Assuntos
Doenças Ósseas Metabólicas/tratamento farmacológico , Doenças Ósseas Metabólicas/etiologia , Dimetil Sulfóxido/uso terapêutico , Ovariectomia/efeitos adversos , Fosfatase Alcalina/sangue , Aminoácidos/sangue , Animais , Densidade Óssea/efeitos dos fármacos , Doenças Ósseas Metabólicas/patologia , Contagem de Células , Dimetil Sulfóxido/farmacologia , Feminino , Glutationa/sangue , Malondialdeído/sangue , Tamanho do Órgão/efeitos dos fármacos , Osteoblastos/efeitos dos fármacos , Osteoblastos/patologia , Osteocalcina/sangue , Osteoclastos/efeitos dos fármacos , Osteoclastos/patologia , Ratos , Ratos Sprague-Dawley , Tíbia/efeitos dos fármacos , Tíbia/enzimologia , Tíbia/patologia
2.
Tissue Cell ; 43(1): 45-51, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21185580

RESUMO

Diabetic nephropathy is the common cause of leading to end stage of renal disease (ESRD). Satureja khozestanica essential oil (SKEO) was used as an antioxidant and antidiabetic for the inhibition of diabetic nephropathy. Forty male rats were uninephrectomized and divided in four groups randomly; group one as control, group two diabetic untreatment, groups three and four treatment with SKEO by 250 or 500 ppm in drinking water, respectively. Diabetes was induced in the second, third and fourth groups by alloxan injection subcutaneously. After eight weeks treatment, serum malondialdehyde, serum creatinine and serum urea were measured. The kidney paraffin sections were stained by periodic acid Schiff method. Glomerular volume and glomerular number were estimated by stereological rules. Glomerular sclerosis was studied semi-quantitatively. The means were compared by SPSS 13 software and Mann-Whitney test at p<0.05. Satureja khozestanica essential oil (250 or 500 ppm) significantly inhibited the progression of glomerular hypertrophy, glomerular number loss, glomerulosclerosis, lipid peroxidation, serum urea and creatinine compared with the diabetic untreated group. The level of glomerular number, serum malondialdehyde, serum creatinine and urea in the treated groups was significantly maintained at the same level as that of the control group. In conclusion, satureja essential oil significantly can ameliorate glomerular hypertrophy, loss of glomerular number, glomerulosclerosis and attenuated serum urea and serum creatinine in diabetic rats.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Nefropatias Diabéticas/tratamento farmacológico , Progressão da Doença , Nefrectomia , Óleos Voláteis/uso terapêutico , Satureja/química , Animais , Creatinina/sangue , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/patologia , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/patologia , Cromatografia Gasosa-Espectrometria de Massas , Glomérulos Renais/efeitos dos fármacos , Glomérulos Renais/patologia , Malondialdeído/metabolismo , Óleos Voláteis/análise , Óleos Voláteis/farmacologia , Tamanho do Órgão/efeitos dos fármacos , Fitoterapia , Ratos , Ureia/sangue
3.
Brain Res ; 1306: 168-75, 2010 Jan 08.
Artigo em Inglês | MEDLINE | ID: mdl-19815005

RESUMO

Recent studies revealed the neuroprotective effects of epigallocatechin gallate (EGCG) on a variety of neural injury .The purpose of this study was to determine the effects of EGCG on the tissue protection and behavioral improvement after spinal cord injury (SCI). Rats were randomly divided into four groups of 18 rats each as follows: sham-operated group, trauma group, and EGCG treatment groups (50 mg/kg, i.p., immediately and 1 hour after SCI). Spinal cord samples were taken 24 hours after injury and studied for determination of malodialdehyde (MDA) levels, immunohistochemistry of Bax and Bcl-2, and TUNEL reaction. Behavioral testing was performed weekly up to 6 weeks post-injury. Then, the rats were euthanized for histopathological assessment. The results showed that MDA levels were significantly decreased in EGCG treatment groups. Greater Bcl-2 and attenuated Bax expression could be detected in the EGCG-treated rats. EGCG significantly reduced TUNEL-positive rate. Also, EGCG significantly reduced the percentage of lesion area and improved behavioral function than the trauma group. On the basis of these findings, we propose that EGCG may be effective in protecting rat spinal cord from secondary injury.


Assuntos
Catequina/análogos & derivados , Discinesias/tratamento farmacológico , Discinesias/patologia , Fármacos Neuroprotetores/farmacologia , Traumatismos da Medula Espinal/tratamento farmacológico , Traumatismos da Medula Espinal/patologia , Animais , Apoptose/efeitos dos fármacos , Catequina/farmacologia , Discinesias/metabolismo , Feminino , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Peroxidação de Lipídeos/efeitos dos fármacos , Testes Neuropsicológicos , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Recuperação de Função Fisiológica , Medula Espinal/metabolismo , Medula Espinal/patologia , Traumatismos da Medula Espinal/metabolismo , Fatores de Tempo , Resultado do Tratamento , Proteína X Associada a bcl-2/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...